Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lu Gan

Showing results (881-890 of 894) with videos related to

Pageof 90
Sort By:
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 19, 2024
A Natural Small Molecule Mitigates Kidney Fibrosis by Targeting Cdc42-mediated GSK-3β/β-catenin SignalingXinrong Hu, Lu Gan, Ziwen Tang, et al.
The Plant Cell|January 18, 2020
<i>GPA5</i> Encodes a Rab5a Effector Required for Post-Golgi Trafficking of Rice Storage ProteinsYulong Ren, Yihua Wang, Tian Pan, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Science Advances|March 11, 2026
Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast nichesJulia Sbierski-Kind, Kelly M Cautivo, Julia Nilsson, et al.
BMC Biology|October 29, 2021
Plastid phylogenomic insights into relationships of all flowering plant familiesHong-Tao Li, Yang Luo, Lu Gan, et al.
Nature|December 17, 2013
D14-SCF(D3)-dependent degradation of D53 regulates strigolactone signallingFeng Zhou, Qibing Lin, Lihong Zhu, et al.
NPJ Digital Medicine|January 27, 2025
Multimodal machine learning enables AI chatbot to diagnose ophthalmic diseases and provide high-quality medical responsesRuiqi Ma, Qian Cheng, Jing Yao, et al.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Cell|January 18, 2025
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patientsLiping Zhong, Lu Gan, Bing Wang, et al.
Med (New York, N.Y.)|July 4, 2024
Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancerHui Wang, Zhuoran Yao, Kai Kang, et al.
Pageof 90

Showing results (881-890 of 894) with videos related to

Sort By:
Pageof 90
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 19, 2024
A Natural Small Molecule Mitigates Kidney Fibrosis by Targeting Cdc42-mediated GSK-3β/β-catenin SignalingXinrong Hu, Lu Gan, Ziwen Tang, et al.
The Plant Cell|January 18, 2020
<i>GPA5</i> Encodes a Rab5a Effector Required for Post-Golgi Trafficking of Rice Storage ProteinsYulong Ren, Yihua Wang, Tian Pan, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Science Advances|March 11, 2026
Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast nichesJulia Sbierski-Kind, Kelly M Cautivo, Julia Nilsson, et al.
BMC Biology|October 29, 2021
Plastid phylogenomic insights into relationships of all flowering plant familiesHong-Tao Li, Yang Luo, Lu Gan, et al.
Nature|December 17, 2013
D14-SCF(D3)-dependent degradation of D53 regulates strigolactone signallingFeng Zhou, Qibing Lin, Lihong Zhu, et al.
NPJ Digital Medicine|January 27, 2025
Multimodal machine learning enables AI chatbot to diagnose ophthalmic diseases and provide high-quality medical responsesRuiqi Ma, Qian Cheng, Jing Yao, et al.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Cell|January 18, 2025
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patientsLiping Zhong, Lu Gan, Bing Wang, et al.
Med (New York, N.Y.)|July 4, 2024
Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancerHui Wang, Zhuoran Yao, Kai Kang, et al.
Pageof 90